自家幹細胞・非幹細胞治療市場：タイプ、適応症、エンドユーザー別-2025-2030年世界予測

自家幹細胞・非幹細胞治療市場は、2023年に46億7,000万米ドルと評価され、2024年には52億8,000万米ドルに達すると予測され、CAGR 14.45％で成長し、2030年には120億1,000万米ドルに達すると予測されています。

自己幹細胞・非自己幹細胞治療の分野では、患者自身の細胞を用いて病気の治療や予防を行う。これらの治療は、再生医療からがんや自己免疫疾患の治療まで、幅広い応用が可能です。これらの治療法の必要性は、拒絶反応の低減、合併症のリスクの低減、個別化された治療アプローチの可能性に起因しており、従来の方法論と比較して大きな利点を提供しています。主要な最終用途分野には、ヘルスケア機関、研究機関、バイオテクノロジー企業などが含まれます。市場成長は、細胞加工における技術的進歩、研究資金の増加、高齢化に伴うアンメット・メディカル・ニーズの高まりに大きく影響されています。さらに、革新的な治療法の承認における規制当局の支援が、こうした治療法の採用をさらに後押ししています。高度な細胞加工技術の開拓や、ヘルスケア制度が不十分な新興国市場への進出にはビジネスチャンスがあります。カスタマイズ可能な治療アプローチや技術共有のための共同研究も、有利な展望をもたらします。しかし市場は、高額な治療費、規制上のハードル、細胞の採取と応用に関する倫理的懸念といった課題に直面しています。さらに、治療の拡張性と一貫した品質管理が複雑さを増しています。技術革新のための最良の道には、細胞の生存率と寿命の改善、送達メカニズムの強化、保管ソリューションの最適化に関する調査が含まれます。さらに、治療法の開発と患者の転帰評価における予測モデリングに機械学習を活用することで、競争上の優位性をもたらすことができます。全体として、自己幹細胞・非自己幹細胞治療市場は、急速な技術革新と有望な成長機会を特徴とするダイナミックな市場であるが、規制状況や倫理的配慮を慎重に通過する必要があります。規制当局や利害関係者と積極的に協力することで、障壁を乗り越え、市場への参入や拡大をよりスムーズに進めることができます。

市場力学：急速に進化する自家幹細胞・非幹細胞治療市場の主要市場インサイトを公開

自家幹細胞・非幹細胞治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の有病率の増加
  • 再生医療技術の進歩
  • 個別化医療に対する認識と受容の高まり
• 市場抑制要因
  • 臨床データが限られているため、自家療法の長期的な有効性が不確実であること
• 市場機会
  • 遺伝子編集技術の調査拡大
  • 政府の支援政策と資金援助が自己幹細胞応用の研究開発を後押し
• 市場の課題
  • 自己幹細胞治療に対する厳しい規制と承認プロセス

ポーターの5つの力：自家幹細胞・非幹細胞治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：自家幹細胞・非幹細胞治療市場における外部からの影響の把握

外部マクロ環境要因は、自家幹細胞・非幹細胞治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析自家幹細胞・非幹細胞治療市場における競合情勢の把握

自家幹細胞・非幹細胞治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス自家幹細胞・非幹細胞治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、自家幹細胞・非幹細胞治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨自家幹細胞・非幹細胞治療市場における成功への道筋を描く

自家幹細胞・非幹細胞治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報に基づいた意思決定を行う上で役立つ重要な質問にも回答しています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加
    • 再生医療技術の進歩
    • 個別化医療に対する認識と受容の高まり
  • 抑制要因
    • 臨床データが限られているため、自己免疫療法の長期的な有効性に関して不確実性が生じている
  • 機会
    • 遺伝子編集技術の調査拡大
    • 政府の支援政策と資金援助により、自己幹細胞応用の研究開発が促進される
  • 課題
    • 自己幹細胞療法に対する厳しい規制上のハードルと承認プロセス
• 市場セグメンテーション分析
  • タイプ：自己幹細胞の進歩、血液学、心血管学、腫瘍学の治療への影響の調査
  • エンドユーザー：自家幹細胞・非幹細胞治療における調査施設の影響
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 自家幹細胞・非幹細胞治療市場：タイプ別

• 自己非幹細胞
  • CAR-T細胞療法
  • 腫瘍浸潤リンパ球
• 自己幹細胞

第7章 自家幹細胞・非幹細胞治療市場適応症別

• がん
• 心血管疾患
• 神経変性疾患
• 整形外科疾患

第8章 自家幹細胞・非幹細胞治療市場：エンドユーザー別

• 外来手術センター
• 病院
• 調査施設

第9章 南北アメリカの自家幹細胞・非幹細胞治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の自家幹細胞・非幹細胞治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの自家幹細胞・非幹細胞治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ブリストル・マイヤーズスクイブ、特定の血液がん治療のための新しいCAR T細胞療法「Breyanzi」でFDAの優先承認を取得
  • FDA、多発性骨髄腫患者に対する新たな幹細胞動員療法を承認
• 戦略分析と提言

企業一覧

• Anterogen Co., Ltd.
• Bluebird Bio, Inc.
• Brainstorm Cell Therapeutics, Inc.
• Caladrius Biosciences, Inc.
• Castle Creek Biosciences Inc.
• Cytori Therapeutics Inc.
• Dendreon Pharmaceuticals LLC
• Gilead Sciences, Inc.
• HCA International Limited
• Hemogenyx Pharmaceuticals PLC
• Hemostemix Inc.
• Jasper Therapeutics, Inc.
• Juventas Therapeutics, Inc.
• Kolon TissueGene, Inc.
• Medipost Co., Ltd.
• NOVADIP Biosciences S.A.
• Novartis AG
• NuVasive, Inc.
• Opexa Therapeutics, Inc.
• Regeneus Ltd. by Cambium-Cambium Bio Limited
• Reliance Life Sciences Pvt. Ltd.
• Stempeutics Research Pvt. Ltd.
• Takeda Pharmaceutical Company Limited
• Vericel Corporation

LIST OF FIGURES

• FIGURE 1. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET RESEARCH PROCESS
• FIGURE 2. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET DYNAMICS
• TABLE 7. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CAR T CELL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS STEM CELLS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY CARDIOVASCULAR DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY NEURODEGENERATIVE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY ORTHOPEDIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY RESEARCH FACILITIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 37. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 59. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 63. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 132. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 148. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 151. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 152. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY AUTOLOGOUS NON-STEM CELLS, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 190. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 191. AUTOLOGOUS STEM CELL & NON-STEM CELL THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

The Autologous Stem Cell & Non-Stem Cell Therapies Market was valued at USD 4.67 billion in 2023, expected to reach USD 5.28 billion in 2024, and is projected to grow at a CAGR of 14.45%, to USD 12.01 billion by 2030.

The field of autologous stem cell and non-stem cell therapies involves using a patient's own cells to treat or prevent diseases. These therapies have broad applications, ranging from regenerative medicine to cancer and autoimmune disorder treatment. The necessity of these therapies stems from their potential for reduced rejection rates, lower risk of complications, and personalized treatment approaches, offering significant advantages over traditional methodologies. Key end-use sectors include healthcare institutions, research organizations, and biotech firms. Market growth is heavily influenced by technological advancements in cell processing, increasing funding for research, and the growing unmet medical needs of aging populations. Moreover, regulatory support in approving innovative therapies is further driving the adoption of these treatment modalities. Opportunities beckon in the development of advanced cell processing techniques and expanding into untapped markets with healthcare system inadequacies. Customizable therapeutic approaches and collaborations for technology sharing also present lucrative prospects. However, the market faces challenges such as high treatment costs, regulatory hurdles, and ethical concerns regarding cell harvesting and application. Moreover, scalability and consistent quality control of therapies add to the complexity. The best paths for innovation include research into improving cell viability and longevity, enhancing delivery mechanisms, and optimizing storage solutions. Additionally, leveraging machine learning for predictive modeling in therapy development and patient outcome assessments can offer competitive advantages. Overall, the market for autologous stem cell and non-stem cell therapies is dynamic, characterized by rapid technological innovations and promising growth opportunities, but requires careful navigation through regulatory landscapes and ethical considerations. Engaging in proactive collaboration with regulatory bodies and stakeholders can help surmount barriers and facilitate smoother market entry and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Autologous Stem Cell & Non-Stem Cell Therapies Market

The Autologous Stem Cell & Non-Stem Cell Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic diseases
  • Advancements in regenerative medicine technology
  • Rising awareness and acceptance of personalized medicine
• Market Restraints
  • Limited clinical data creating uncertainty regarding the long-term efficacy of autologous therapies
• Market Opportunities
  • Expanding research in gene editing technology
  • Supportive government policies and funding boost R&D in autologous stem cell applications
• Market Challenges
  • Stringent Regulatory hurdles & approval process for autologous stem cell therapies

Porter's Five Forces: A Strategic Tool for Navigating the Autologous Stem Cell & Non-Stem Cell Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Autologous Stem Cell & Non-Stem Cell Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Autologous Stem Cell & Non-Stem Cell Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Autologous Stem Cell & Non-Stem Cell Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Autologous Stem Cell & Non-Stem Cell Therapies Market

A detailed market share analysis in the Autologous Stem Cell & Non-Stem Cell Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Autologous Stem Cell & Non-Stem Cell Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Autologous Stem Cell & Non-Stem Cell Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Autologous Stem Cell & Non-Stem Cell Therapies Market

A strategic analysis of the Autologous Stem Cell & Non-Stem Cell Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Autologous Stem Cell & Non-Stem Cell Therapies Market, highlighting leading vendors and their innovative profiles. These include Anterogen Co., Ltd., Bluebird Bio, Inc., Brainstorm Cell Therapeutics, Inc., Caladrius Biosciences, Inc., Castle Creek Biosciences Inc., Cytori Therapeutics Inc., Dendreon Pharmaceuticals LLC, Gilead Sciences, Inc., HCA International Limited, Hemogenyx Pharmaceuticals PLC, Hemostemix Inc., Jasper Therapeutics, Inc., Juventas Therapeutics, Inc., Kolon TissueGene, Inc., Medipost Co., Ltd., NOVADIP Biosciences S.A., Novartis AG, NuVasive, Inc., Opexa Therapeutics, Inc., Regeneus Ltd. by Cambium - Cambium Bio Limited, Reliance Life Sciences Pvt. Ltd., Stempeutics Research Pvt. Ltd., Takeda Pharmaceutical Company Limited, and Vericel Corporation.

Market Segmentation & Coverage

This research report categorizes the Autologous Stem Cell & Non-Stem Cell Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Autologous Non-Stem Cells and Autologous Stem Cells. The Autologous Non-Stem Cells is further studied across Car T Cell Therapies and Tumor Infiltrating Lymphocyte.
• Based on Indication, market is studied across Cancer, Cardiovascular Disease, Neurodegenerative Disorders, and Orthopedic Diseases.
• Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Research Facilities.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases
    • 5.1.1.2. Advancements in regenerative medicine technology
    • 5.1.1.3. Rising awareness and acceptance of personalized medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Limited clinical data creating uncertainty regarding the long-term efficacy of autologous therapies
  • 5.1.3. Opportunities
    • 5.1.3.1. Expanding research in gene editing technology
    • 5.1.3.2. Supportive government policies and funding boost R&D in autologous stem cell applications
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent Regulatory hurdles & approval process for autologous stem cell therapies
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Exploring Advancements in Autologous Stem Cell, Impacts on Hematological, Cardiovascular, and Oncology Treatments
  • 5.2.2. End-User: Impact of Research Facilities in Autologous Stem Cell & Non-Stem Cell Therapies
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Type

• 6.1. Introduction
• 6.2. Autologous Non-Stem Cells
  • 6.2.1. Car T Cell Therapies
  • 6.2.2. Tumor Infiltrating Lymphocyte
• 6.3. Autologous Stem Cells

7. Autologous Stem Cell & Non-Stem Cell Therapies Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular Disease
• 7.4. Neurodegenerative Disorders
• 7.5. Orthopedic Diseases

8. Autologous Stem Cell & Non-Stem Cell Therapies Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Hospitals
• 8.4. Research Facilities

9. Americas Autologous Stem Cell & Non-Stem Cell Therapies Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Autologous Stem Cell & Non-Stem Cell Therapies Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Autologous Stem Cell & Non-Stem Cell Therapies Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Bristol Myers Squibb Gets FDA Fast-Track for New CAR T Cell Therapy Breyanzi to Treat Certain Blood Cancers
  • 12.3.2. FDA Approves New Stem Cell Mobilization Therapy for Multiple Myeloma Patients
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Anterogen Co., Ltd.
• 2. Bluebird Bio, Inc.
• 3. Brainstorm Cell Therapeutics, Inc.
• 4. Caladrius Biosciences, Inc.
• 5. Castle Creek Biosciences Inc.
• 6. Cytori Therapeutics Inc.
• 7. Dendreon Pharmaceuticals LLC
• 8. Gilead Sciences, Inc.
• 9. HCA International Limited
• 10. Hemogenyx Pharmaceuticals PLC
• 11. Hemostemix Inc.
• 12. Jasper Therapeutics, Inc.
• 13. Juventas Therapeutics, Inc.
• 14. Kolon TissueGene, Inc.
• 15. Medipost Co., Ltd.
• 16. NOVADIP Biosciences S.A.
• 17. Novartis AG
• 18. NuVasive, Inc.
• 19. Opexa Therapeutics, Inc.
• 20. Regeneus Ltd. by Cambium - Cambium Bio Limited
• 21. Reliance Life Sciences Pvt. Ltd.
• 22. Stempeutics Research Pvt. Ltd.
• 23. Takeda Pharmaceutical Company Limited
• 24. Vericel Corporation